The agenda includes:
Preparing a position on the legitimacy of granting reimbursement approval for the medicinal product Livmarli (maralixibat) for the indication: pruritus of the skin in Alagille syndrome.
Preparing an opinion on draft health policy programmes of local government units:
- “Prevention of overweight and obesity in children in class III of primary schools in the Municipality of Kolobrzeg for 2022/2024”,
- “Comprehensive rehabilitation and therapy for children with disabilities from the Municipality of Mszana”,
- “Programme for prevention and correction of posture defects in school-age children »Healthy Spine«” (Miedźna Municipality).
Preparing an opinion on the inclusion in the reimbursement of medicines containing the active substances:
- cetirizinum for the following indications: atopic dermatitis; food allergy – in patients from 6 months of age; anaphylactic reaction manifested by urticaria or Quincke’s edema – in patients from 6 months of age,
- levocetirizini dihydrochloridum for the following indications: atopic dermatitis; food allergy – in patients from 6 months of age; anaphylactic reaction manifested by urticaria or Quincke’s edema – in patients from 6 months of age,
- loratadinum for the following indications: atopic dermatitis – in patients from 2 years of age; food allergy – in patients from 2 years of age; anaphylactic reaction manifested by urticaria or Quincke’s edema –– in patients from 2 years of age,
- acidum folicum for the indication: psoriasis – in patients treated with methotrexate,
- leflunomidum for the indication: juvenile idiopathic arthritis – polyarticular form after failure of therapy or in case of methotrexate intolerance.